TABLE 2.

Consensus recommendations for treatment of PsA domains

Domain	Recommended therapeutic options (strongly recommended)	Other therapeutic options (conditionally recommended)	To be avoided (strongly not recommended)
Peripheral arthritis DMARD‐naïve 9 , 11 , 33	csDMARD TNFi PDE‐4i IL‐12/23i IL‐17i IL‐23i JAKi	NSAIDs GCCs (oral or IA) CTLA‐4 Ig
Peripheral arthritis DMARD inadequate response 9 , 10 , 34 , 48 , 49	TNFi PDE‐4i IL‐12/23i IL‐17i IL‐23i JAKi	NSAIDs GCCs (oral or IA) csDMARD CTLA‐4 Ig
Peripheral arthritis, inadequate response to biological treatment 9 , 54	TNFi IL‐17i IL‐12/23i IL‐23i JAKi	NSAID GCC (oral and IA) PDE‐4i CTLA‐4 Ig
Axial PsA 9 , 50 , 51 , 52	NSAIDs and simple analgesia Physiotherapy TNFi IL‐17i JAKi	GCC injection for sacroiliac joints Bisphosphonate	csDMARD IL‐12/23i
Enthesitis 9 , 10 , 49 , 58 , 59 , 60 , 61 , 62	TNFi IL‐17i JAKi IL‐23i IL‐12/23i	NSAIDs physiotherapy MTX CTLA‐4 Ig PDE‐4i
Dactylitis 9 , 54 , 58 , 62 , 63	TNFi IL‐17i IL12/23i IL‐23i JAKi PDE‐4i	NSAIDs GCCs injections MTX CTLA‐4 Ig
Nail disease 9 , 10 , 64 , 65 , 66 , 68 , 69	TNFi IL‐17i PDE‐4i IL‐12/23i IL‐23i
Skin disease (plaque) 9 , 119 , 120 , 121 , 122 , 123	Topical therapies, phototherapy Acitretin csDMARDs (MTX, LEF, CSA) TNFi IL‐12/23i IL‐17i IL‐23i JAKi PDE‐4i

Abbreviations: CSA, cyclosporine; CTLA‐4 Ig, cytotoxic T lymphocyte‐associated antigen‐4 immunoglobulin; DMARD, disease‐modifying antirheumatic drug; GCC, glucocorticoids; IA, intra‐articular; IL‐12/23i, interleukin‐12/23 inhibitor; IL‐17i, interleukin‐17 inhibitor; IL‐23i, interleukin‐23 inhibitor; IV, intravenous; JAKi, Janus kinase inhibitor; LEF, leflunomide; MTX, methotrexate; NSAIDs, non‐steroidal anti‐inflammatory drugs; PsA, psoriatic arthritis; PDE‐4i phosphodiesterase‐4 inhibitor (apremilast); SC, subcutaneous; TNFi, tumor necrosis factor inhibitor.